Excess psoriasis and psoriatic arthritis mortality during the COVID‐19 pandemic in the United States: A nationwide population‐based study from 2010 to 2021

Abstract

AbstractBackgroundLittle is known about mortality trends among patients with psoriasis (PsO) and psoriatic arthritis (PsA) in the United States.ObjectivesTo ascertain mortality trends of PsO and PsA between 2010 and 2021, focusing on the effects of the COVID‐19 pandemic.MethodsWe collected data from the National Vital Statistic System and calculated age‐standardized mortality rates (ASMR) and cause‐specific mortality for PsO/PsA. We evaluated observed versus predicted mortality for 2020–2021 based on trends from 2010 to 2019 with joinpoint and prediction modelling analysis.ResultsAmong 5810 and 2150 PsO‐ and PsA‐related deaths between 2010 and 2021, ASMR for PsO dramatically increased between 2010–2019 and 2020–2021 (annual percentage change [APC] 2.07% vs. 15.26%; p < 0.01), leading to a higher observed ASMR (per 100,000 persons) than predicted for 2020 (0.27 vs. 0.22) and 2021 (0.31 vs. 0.23). The excess mortality of PsO was 22.7% and 34.8% higher than that in the general population in 2020 (16.4%, 95% CI: 14.9%–17.9%) and 2021 (19.8%, 95% CI: 18.0%–21.6%) respectively. Notably, the ASMR rise for PsO was most pronounced in the female (APC: 26.86% vs. 12.19% in males) and the middle‐aged group (APC: 17.67% vs. 12.47% in the old‐age group). ASMR, APC and excess mortality for PsA were similar to PsO. SARS‐CoV‐2 infection contributed to more than 60% of the excess mortality for PsO and PsA.ConclusionsIndividuals living with PsO and PsA were disproportionately affected during the COVID‐19 pandemic. Both ASMRs increased at an alarming rate, with the most pronounced disparities among the female and middle‐aged groups.